Bavarian Nordic presents new preclinical data for Covid-19 vaccine

Bavarian Nordic's first clinical studies with a vaccine for Covid-19 are almost ready. Ahead of launch, the firm has received a batch of positive preclinical data. This confirms the potential, according to Bavarian Nordic's CEO Paul Chaplin.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Bavarian Nordic is getting ready for its first in-human trial with the vaccine, which the firm in-licensed from Adaptvac, and now, in the first round, new data has arrived.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading